<DOC>
	<DOCNO>NCT01655563</DOCNO>
	<brief_summary>Tacrolimus standard widely use maintenance immunosuppressive agent solid organ transplantation.The purpose trial determine dose tacrolimus genetics help early attainment maintenance correct dosage level early post-transplant period . This pilot dose-finding trial help determine dose strategy guide genotype age solid organ transplant recipient validate multi-centre trial immediate next step . The study hypothesize dosage level determine age genotype attain faster accurately standard dose procedure 14-days transplant . Further , study hypothesizes genotype age dose strategy cause faster recovery ( test kidney ' ability clear creatine blood ) result low frequency adverse effect rejection transplant .</brief_summary>
	<brief_title>Pharmacogenetic Trial Tacrolimus After Pediatric Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Age &lt; 18 year old Assessed and/or list heart , kidney , liver transplantation Planned oral enteral maintenance immunosuppression tacrolimus post transplant Informed consent legal guardian Contraindications oral enteral tacrolimus Comorbidities preclude standard dosing e.g . significant renal hepatic insufficiency Participation investigational drug trial within 30 day study initiation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
</DOC>